Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Letter from the Editor Next Article
Glycans as novel immunomodulators in inflammatory bowel disease »
« Letter from the Editor Next Article
Glycans as novel immunomodulators in inflammatory bowel disease »
Table of Contents: SPIN 2019
Featured articles
Letter from the Editor
Aetiology: Triggers and Risk Factors
Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis
Atopic dermatitis and psoriasis: on a spectrum?
Advances in Therapy
Advances in target-oriented therapy: psoriatic arthritis
Favourable safety profile of long-term use of ixekizumab
Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies
Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients
Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis
Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease
Novel Considerations
Granulomatous rosacea: exploratory histological markers
Live imaging of cutaneous immune responses
Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?
ABP501 biosimilar for adalimumab: What you need to know
Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis
Small molecules, apremilast, and TYK2
Related Articles
December 9, 2019
IL-17A blocker effective in paediatric psoriasis patients
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy